Specialty RxSpecialty RxSpecialty Rx
A plain-language look at what these compounds are, and — separately — a look at what the published research actually shows.
A synthetic peptide first described in 1993 and one of the most-studied compounds in this category — a 2024 literature review cites over 130 studies on tendon, muscle, ligament, and gut-lining healing.[1][2] Human research is still in its early stages, with small reported cases rather than large controlled trials so far.
Marketed as related to a naturally occurring tissue-repair protein (thymosin beta-4).[1] Human trial results haven't been published yet.
A small peptide fragment studied for its anti-inflammatory effects on the gut lining.[1] It's also sold combined with BPC-157 and TB-500 in this catalog's blend products.
Pairs BPC-157 and TB-500 with KPV (see each above) in one blend for recovery-focused protocols.[1] The combination itself hasn't been separately studied — see each ingredient's entry above.
Combines BPC-157 and TB-500 (see their entries above) in one vial. This specific pairing hasn't been separately studied — the research so far applies to each ingredient on its own.
Brings together GHK-Cu, BPC-157, and TB-500 (see their entries above) for recovery and skin goals together. This exact combination hasn't been studied as a blend — the evidence that exists is for each ingredient individually.
Combines TB-500, BPC-157, GHK-Cu, and KPV — all covered above — into one product. This exact combination hasn't been studied as a blend; the evidence that exists is for each ingredient on its own.
Developed by a Russian research group studying telomerase activity and aging biomarkers.[1] Human data includes an observational cohort followed over several years and an open-label eye-health study,[2] both encouraging early signals rather than the placebo-controlled trials Western regulators typically require.
A naturally occurring copper-binding peptide and a familiar ingredient in cosmetic skincare — a randomized, double-blind trial found a copper-peptide formulation improved measures of photoaged skin.[1] Its use for broader medical wound healing is earlier-stage.[2]
A mitochondrial-derived peptide first characterized in 2015, with promising early data on metabolism.[1] A placebo-controlled human trial is currently in progress — results aren't published yet, so this is an active, developing area of research.
Made naturally in the body from three amino acids. Oral and topical studies on skin brightening have shown some positive results;[1] evidence for broader antioxidant or energy-support use is still developing — a small trial testing IV glutathione for Parkinson's disease, for example, didn't show a clear benefit over placebo.[2]
Your cells already make and rely on NAD+ for energy production. Related oral supplements (like NMN) have some human trial data with mixed results;[1] a recent review found the injectable/IV form specifically hasn't yet been tested in controlled human trials[2] — worth knowing as an evidence gap, not a mark against it.
Has real human trial history, including a completed pivotal trial supporting its use for Barth syndrome, a rare genetic muscle disease.[1] Trials exploring other uses, like an eye condition called dry age-related macular degeneration, are ongoing with mixed results so far[2] — promising research, not yet a general longevity claim.
Studied for its role in protecting brain cells from oxidative stress.[1] One small human study in older adults reported benefits on aging-related markers[2] — an encouraging early signal, ahead of larger placebo-controlled trials.
A growth-hormone-releasing hormone (GHRH) analog that stimulates the body's own growth hormone secretion, with its best-established effect being a reduction in visceral (abdominal) fat, based on Phase 3 clinical trials.[1] Its best-documented clinical use is specifically for HIV-associated lipodystrophy; use for general weight loss or body-composition goals falls outside that studied population.
Two compounds often used together to support the body's own growth hormone release. CJC-1295 has placebo-controlled human data on hormone levels;[1] Ipamorelin was studied in a gut-motility recovery trial.[2] Neither has been studied for this specific use in a dedicated clinical trial.
Combines Tesamorelin and Ipamorelin (see their entries above) in one product. This specific pairing hasn't been separately studied — the research so far applies to each ingredient on its own.
Acts on three metabolic hormone receptors at once and is being developed by a major pharmaceutical company for obesity and type 2 diabetes. A published Phase 2 trial showed substantial weight loss over about a year,[1] and Phase 3 trials are underway now.[2] It's still investigational, with evidence so far limited to those trials.
Compounded semaglutide is not FDA-approved and is not considered the same as, equivalent to, or a generic version of an FDA-approved drug. When legally available, a licensed provider may determine whether a compounded preparation is clinically appropriate for an individual patient.
Compounded tirzepatide is not FDA-approved and is not considered the same as, equivalent to, or a generic version of an FDA-approved drug. When legally available, a licensed provider may determine whether a compounded preparation is clinically appropriate for an individual patient.
A modified fragment of human growth hormone originally developed for weight loss. Its largest human trial didn't show a clear weight difference over placebo,[1] and its current compounding status is unsettled[2] — worth confirming directly with your pharmacy before purchase.
Has a long history of clinical use dating to a 1997 pediatric diagnostic application,[1] though that product was later discontinued for business reasons.[2] Today it's available as a compounded preparation, used off-label in adults for growth-hormone support.
Comes in two forms — a longer-lasting version (with DAC) and a faster-clearing version (Mod GRF 1-29, without DAC). Human data shows it reliably raises growth hormone and IGF-1 levels;[1] it hasn't yet been studied for a specific health outcome in a larger trial.
Prompts the body to release more of its own growth hormone.[1] Human data is limited to one discontinued trial for an unrelated gut-recovery use;[2] it hasn't yet been tested in dedicated trials for weight, muscle, or recovery goals.
Developed and registered as a pharmaceutical in Russia, with published clinical studies on stroke recovery, cerebrovascular protection, and cognitive function.[1] It hasn't yet been evaluated in a Western-standard clinical trial.
A peptide with a long research history in sleep regulation, though its exact mechanism is still being studied. Small human studies from the 1980s–90s showed modest results on sleep[1] and on easing withdrawal symptoms.[2]
Developed by the same Russian institute behind Semax. A small clinical trial found effects similar to a standard anti-anxiety medication, without the same sedation,[1] and it's used clinically there. It hasn't yet been evaluated in a Western-standard clinical trial.
Used to help people with a rare light-sensitivity disorder tolerate more sun exposure.[1] Its use includes periodic skin monitoring, since it affects pigmentation — worth knowing this is a different clinical use than tanning or libido.
Part of the body's own immune defense. Human trials for chronic wound healing have shown mixed results — a benefit appeared mainly in a smaller subgroup of one study.[1] Separate research also links this peptide to certain autoimmune conditions,[2] so the fuller picture is still developing.
Marketed abroad for chronic hepatitis and as a cancer-treatment adjunct in some countries; not an approved product in the US. COVID-19 research on it has been mixed, without a clear signal either way in the largest pooled analysis.[1]
Made from a peptide-nucleoprotein complex derived from young-animal adrenal tissue, based on the theory that specific peptides can support gene expression in the matching organ. Independently published human research under this exact product name hasn't been found yet — the broader Khavinson research tradition (see Epitalon above) is the closest related evidence base.
From the same Khavinson research tradition as Epitalon. A small study of older adults with jaw-joint disease reported improvement using this peptide as part of a combined treatment plan[1] — the most human data of any product in this group, though not tested alone or against placebo.
From the same Khavinson research tradition as Epitalon, aimed at the brain and nervous system. It's sometimes confused with a related, better-studied product (Cortexin) from the same research group — that product's evidence doesn't carry over to this one specifically.
From the same Khavinson research tradition as Epitalon, aimed at liver-cell metabolism. Independently published human research under this specific product name hasn't been found yet.
From the same Khavinson research tradition as Epitalon, aimed at muscle tissue. Independently published human research under this specific product name hasn't been found yet.
From the same Khavinson research tradition as Epitalon, aimed at ovarian tissue. Independently published human research under this specific product name hasn't been found yet.
From the same Khavinson research tradition as Epitalon. This is a different product from Pinealon (an injectable/spray version covered under Longevity above); independently published human research under this specific capsule product hasn't been found yet.
From the same Khavinson research tradition as Epitalon, aimed at thyroid function. Independently published human research under this specific product name hasn't been found yet.
In use since 1959 as a short-term (a few weeks) adjunct to diet and exercise — the label has never been updated for the long-term use it's often prescribed for today.[1] A Schedule IV controlled substance; contraindicated with MAOIs and in cardiovascular disease, hyperthyroidism, and glaucoma.
Used (since 2012) for chronic weight management. Carries a boxed warning for fetal harm — contraindicated in pregnancy, requires pregnancy testing — plus warnings for suicidal ideation and acute vision changes; available only through a REMS program.
Used (since 2014) for chronic weight management, acting on hypothalamic appetite centers and reward pathways. Carries a boxed warning for suicidal thoughts/behavior (a bupropion class warning) and is contraindicated in seizure disorders, eating disorders, and opioid use or withdrawal.
Available as a prescription (since 1999) and OTC (since 2007) fat-absorption blocker.[1] In 2010 a safety warning was added about rare severe liver injury after postmarketing reports, though a causal link was never established; common side effects are gastrointestinal.
Used for chronic weight management in adults (since 2014) and adolescents 12+ (since 2020) — an earlier, shorter-acting relative of semaglutide.[1] Carries a boxed warning for thyroid C-cell tumors seen in rodent studies (human relevance unknown); contraindicated with a personal/family history of medullary thyroid carcinoma or MEN2 syndrome.
Used (since 2020) only for chronic weight management in patients with obesity from confirmed POMC, PCSK1, or LEPR gene deficiency — rare genetic conditions, not general-population obesity. Not appropriate outside that confirmed genetic indication.
Used for type 2 diabetes; weight-loss use is off-label. A 2024 meta-analysis of randomized trials found modest weight loss on metformin alone (roughly 3-5%, ~3.4 kg average).[1] Generally well-tolerated, with GI side effects and a rare lactic-acidosis risk in kidney impairment.
A GABA-A receptor-acting sleep medication.[1] Carries a boxed warning for complex sleep behaviors (sleep-walking, sleep-driving, and similar activities performed while not fully awake, some resulting in serious injury or death) — contraindicated in anyone who has previously experienced these.
A non-benzodiazepine "Z-drug" (in use since 2004).[1] Shares the class warning for complex sleep behaviors and next-day drowsiness; lowest effective dose is recommended, particularly for older adults.
Used for major depressive disorder; the low dose (25-100 mg, versus 150-600 mg for depression) used for sleep is off-label. Reviews report it increases slow-wave sleep and is widely used for insomnia, but note a lack of large randomized trials for insomnia specifically as a standalone indication.[1] Not a controlled substance; side effects include daytime sedation and, rarely, priapism.
The first melatonin-receptor-agonist sleep medication (in use since 2005).[1] Has no meaningful affinity for GABA/benzodiazepine receptors, distinguishing its mechanism and abuse-risk profile from Z-drugs; not a controlled substance. Not indicated for staying-asleep (sleep-maintenance) insomnia.
The first orexin-receptor-antagonist sleep medication, working by reducing the brain's wake drive rather than direct sedation.[1] Label warnings include next-day impairment, worsening depression/suicidal ideation, and complex sleep behaviors; dosing is capped at 20 mg/night.
Used (since 2010) at a low dose (3-6 mg) that selectively blocks histamine receptors rather than acting as a full antidepressant.[1] Not a controlled substance; the tricyclic-antidepressant boxed warning for youth suicidality applies at higher (antidepressant) doses, not the 3-6 mg insomnia dose.
Used for seizures and nerve pain; sleep use is off-label. Small studies found it increased slow-wave sleep and modestly reduced night-time waking,[1] but evidence is limited to small trials, not large confirmatory research — not considered a first-line insomnia treatment.
Regulated as an OTC dietary supplement, so potency and purity aren't independently verified the way a prescription drug's would be. An NIH-cited meta-analysis of 19 trials found small but real reductions in time to fall asleep (~7 minutes) and increases in total sleep time (~8 minutes);[1] long-term safety isn't established, and accidental overdose in children is a known risk given OTC availability.
No SARM has ever been approved for any use; sold illegally as "research chemicals" and banned in competitive sport. Regulators have issued repeated warnings citing liver injury, and a systematic review documented cases of liver injury, muscle breakdown, and tendon rupture in recreational users.[1] Included here for education only — not a product this pharmacy dispenses.
Used only for specific medical conditions (growth hormone deficiency, Turner syndrome, and others); distributing it for athletic enhancement or anti-aging without a prescription is a federal offense.[1] Off-label performance use lacks strong evidence of benefit and carries serious cardiovascular risk.
One of the most-studied sports supplements, with a strong safety record in healthy people.[1] Most effective for brief, intense or resistance exercise; evidence for endurance/aerobic benefit is weaker. Caution is advised for those with pre-existing kidney disease.
Used for anemia from chronic kidney disease or chemotherapy; prohibited at all times in competitive sport, with exemptions available for genuine medical need.[1] Misuse for endurance "blood doping" thickens the blood, raising the risk of heart attack, stroke, and blood clots.